Industries
Politics & Economics
Newsletters
Sign in
Subscribe
Drugmakers
COVID-19
After Slow Start, States Are Flush With COVID-19 Antiviral Pills. But Federal Data Shows Some Are Slow to Give Them Out
COVID-19
2 in 3 Democrats and 2 in 5 Republicans Back Proposal to Waive COVID-19 Vaccine Patent Rights
Drug Pricing
Incoming PhRMA Chair Expects Drugmakers to Face ‘Some Pain’ in 2022 Amid Reform and Efforts to Rebuild Patient Trust
Drugmakers
Clinical Trials Are Slow and Expensive. Industry Leaders Want That to Change in 2022
COVID-19
The FDA Is Expected to Authorize COVID-19 Antiviral Pills. 3 in 4 Adults Say They’d Take Them if They Got Sick
Drugmakers
As Threat of Antibiotic Resistance Mounts, Biotechs Are Running Out of Cash and Time
Congressional Politics
In Oklahoma, A Warning for Proponents of Value-Based Pharma Payment
Congressional Politics
As Drug Prices Soar, Policymakers Eye Dose of Government Intervention